Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma
Figure 5
In vitro cell viability of LMS cell lines treated with bortezomib. LMS03, LMS04, and LMS05 were exposed to bortezomib at concentrations ranging from 0 to10 M. Cell viability was assessed 72 h after exposure to drugs using WST-1 assays and experiments were performed in triplicate.